Department of Gastroenterology, Instituto Portugues de Oncologia, Porto, Portugal.
Department of Digestive Diseases, Hôpital Edouard Herriot, Lyon, France.
Endoscopy. 2015 Sep;47(9):829-54. doi: 10.1055/s-0034-1392882. Epub 2015 Aug 28.
This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system 1 2 was adopted to define the strength of recommendations and the quality of evidence.
1 ESGE recommends endoscopic en bloc resection for superficial esophageal squamous cell cancers (SCCs), excluding those with obvious submucosal involvement (strong recommendation, moderate quality evidence). Endoscopic mucosal resection (EMR) may be considered in such lesions when they are smaller than 10 mm if en bloc resection can be assured. However, ESGE recommends endoscopic submucosal dissection (ESD) as the first option, mainly to provide an en bloc resection with accurate pathology staging and to avoid missing important histological features (strong recommendation, moderate quality evidence). 2 ESGE recommends endoscopic resection with a curative intent for visible lesions in Barrett's esophagus (strong recommendation, moderate quality evidence). ESD has not been shown to be superior to EMR for excision of mucosal cancer, and for that reason EMR should be preferred. ESD may be considered in selected cases, such as lesions larger than 15 mm, poorly lifting tumors, and lesions at risk for submucosal invasion (strong recommendation, moderate quality evidence). 3 ESGE recommends endoscopic resection for the treatment of gastric superficial neoplastic lesions that possess a very low risk of lymph node metastasis (strong recommendation, high quality evidence). EMR is an acceptable option for lesions smaller than 10 - 15 mm with a very low probability of advanced histology (Paris 0-IIa). However, ESGE recommends ESD as treatment of choice for most gastric superficial neoplastic lesions (strong recommendation, moderate quality evidence). 4 ESGE states that the majority of colonic and rectal superficial lesions can be effectively removed in a curative way by standard polypectomy and/or by EMR (strong recommendation, moderate quality evidence). ESD can be considered for removal of colonic and rectal lesions with high suspicion of limited submucosal invasion that is based on two main criteria of depressed morphology and irregular or nongranular surface pattern, particularly if the lesions are larger than 20 mm; or ESD can be considered for colorectal lesions that otherwise cannot be optimally and radically removed by snare-based techniques (strong recommendation, moderate quality evidence).
本指南是欧洲胃肠道内镜学会(ESGE)的官方声明。采用推荐评估、制定与评估(GRADE)系统 1 2 来定义推荐的强度和证据的质量。
ESGE 建议对浅表性食管鳞状细胞癌(SCC)进行内镜整块切除,不包括明显黏膜下受累的 SCC(强烈推荐,中等质量证据)。如果可以确保整块切除,小于 10mm 的此类病变可考虑内镜黏膜切除术(EMR)。然而,ESGE 建议内镜黏膜下剥离术(ESD)作为首选方法,主要是为了提供整块切除,并进行准确的病理分期,避免错过重要的组织学特征(强烈推荐,中等质量证据)。
ESGE 建议对 Barrett 食管中可见病变进行内镜下根治性切除(强烈推荐,中等质量证据)。ESD 并未显示在切除黏膜癌方面优于 EMR,因此应首选 EMR。对于大于 15mm、抬举不良的肿瘤和有黏膜下浸润风险的病变等特殊病例,可考虑 ESD(强烈推荐,中等质量证据)。
ESGE 建议对具有极低淋巴结转移风险的胃浅表性肿瘤进行内镜下切除(强烈推荐,高质量证据)。EMR 是直径小于 10-15mm、高级别组织学概率极低的病变的一种可接受的选择(巴黎 0-IIa)。然而,ESGE 建议 ESD 作为大多数胃浅表性肿瘤的治疗选择(强烈推荐,中等质量证据)。
ESGE 指出,大多数结肠和直肠的浅表性病变可以通过标准息肉切除术和/或 EMR 进行有效的治愈性切除(强烈推荐,中等质量证据)。如果基于凹陷形态和不规则或非颗粒状表面模式这两个主要标准,怀疑存在局限性黏膜下浸润的结肠和直肠病变较大(大于 20mm),可以考虑进行 ESD 切除;或如果其他方法不能通过圈套器技术进行最佳和根治性切除的结直肠病变,可以考虑 ESD 切除(强烈推荐,中等质量证据)。